Search Our Website
Evaluate Your Case Today
Calcagno & Associates
900 South Avenue, 3rd Floor
Staten Island, NY, 10314
Phone: 1-800-WE-FIGHT
(718) 568-3585
By appointment only
Battery Place
New York, NY, 10004
Phone: (800) 933-4448
Grand Concourse Bronx, NY, 10451 Phone: (718) 933-4448
Bay Parkway Brooklyn, NY, 11214 Phone: (800) 487-6837
Ortho Evra, manufactured by Johnson & Johnson / Ortho McNeil, is a transdermal birth control patch that is worn on the torso and delivers hormones through absorption into the skin. The patch releases ethinyl estradiol (an estrogen hormone) and norelgestromin (a progestin hormone) through the skin into the blood stream. Approved in 2001, the patch was originally touted by its manufacturer as having similar side effects to oral contraceptive pills. However, Ortho Evra is associated with a higher risk of such adverse cardiovascular events as blood clots, heart attack and stroke.
In November 2005, the FDA and Johnson & Johnson updated Ortho Evra’s label to warn consumers about the higher risk associated with the patch due to higher exposure to estrogen than with oral contraceptives. The FDA indicated that due to the patch’s hormones being released directly into the bloodstream, women are exposed to 60% more estrogen than if oral contraceptives containing 35 micrograms of estrogen were taken orally and digested. Ortho Evra is supposed to release 150 mcg of norelgestromin and 20 mcg of ethinyl estradiol into the bloodstream each day.
Ortho Evra has been associated with high blood clot rates. Blood clots can lead to serious and life-threatening complications.
Ortho Evra appears to cause blood clots at a much higher rate than oral contraceptive pills. This increased risk was not disclosed to women and has caused many unnecessary injuries and deaths since the patch’s approval.
If you or a loved one have been affected, get Ortho Evra legal help today.
Our law firm is available 24/7 to answer any Ortho Evra claim questions you may have. Contact us today for a free, no obligation, Ortho Evra legal consultation by completing the case evaluation form on the right side of this page or by calling 1-800-WE-FIGHT (1-800-933-4448).
Return to Defective Drugs Listing